A Phase 1, Open-Label, Randomized, Single Dose, 3-Period, 3-Treatment Study to Evaluate the Relative Bioavailability of D-0502 Tablet Formulations in Healthy Female Subjects
Latest Information Update: 11 Aug 2022
At a glance
- Drugs Taragarestrant (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors InventisBio
- 05 Aug 2022 Status changed from active, no longer recruiting to completed.
- 13 May 2022 Planned End Date changed from 1 Apr 2022 to 18 Jul 2022.
- 14 Feb 2022 New trial record